DXR

DAXOR CORP 10-Q Summary: Quarter Ended March 31, 2006

Business Context and Reporting Period

This Form 10-Q covers the three-month period ended March 31, 2006. DAXOR Corporation is a medical device manufacturer focused on the Blood Volume Analyzer (BVA-100) and cryobanking services (blood and semen storage) through its subsidiary, Scientific Medical Systems Corp. The company relies heavily on a substantial investment portfolio to offset operating losses from its core medical business.

Key Financial Metrics

Segment Performance: Equipment Sales & Related Services generated $212,578 in revenue but incurred an operating loss of $1,280,832. Cryobanking & Related Services generated $129,568 in revenue with a small operating profit of $8,713. Investment Activity contributed $1,327,450 in net income, primarily driven by dividends ($550,822) and gains on sales of securities ($710,201).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 13.9% year-over-year, driven by a 26% increase in sales of Volumex kits (radioactive doses used with the BVA-100). No BVA-100 instruments were sold in the quarter, though six trial agreements were signed.
• Profitability: The company moved from a gross loss in Q1 2005 to a gross profit in Q1 2006. The Net Loss improved significantly from $(470,127) to $(38,982), largely due to a 64.6% increase in investment income.
• Restatements: Q1 2005 figures were restated to correct accounting errors regarding the valuation of options/short sales, capitalization of equipment, and revenue recognition for cryobanking (switching from cash to accrual basis).
• Liquidity: Cash and cash equivalents decreased from $93,003 at year-end 2005 to $37,818 at March 31, 2006. Net cash used in operating activities was $(1,448,768), partially offset by net cash provided by investing activities of $2,627,127.

Outlook, Risks, and Management Commentary

• Medicare Reimbursement: A 2005 Medicare error regarding Volumex kit reimbursement was corrected in early 2006. Management expects this to improve hospital acceptance and conversion of trial agreements to sales.
• Strategic Initiatives: The company is negotiating "Blood Optimization Programs" (BOP) with hospitals, combining blood volume analysis with autologous blood storage. R&D continues on Glomerular Filtration Rate (GFR) testing and a needle-free delivery device ("Max-200").
• Investment Strategy: The portfolio (approx. $57.6M fair value) remains the primary source of capital preservation and income. It consists primarily of utility stocks. The company utilizes covered calls, put options, and limited short sales (max 5% of portfolio) to enhance returns.
• Internal Controls: Management disclosed ineffective internal controls over financial reporting due to insufficient personnel expertise in US GAAP. This led to restatements of prior periods. A new Controller (CPA) and temporary external CPAs have been hired to remediate these issues.
• Liquidity Risk: While the investment portfolio provides a buffer, management warns that simultaneous expansion of marketing, R&D, and potential acquisitions could lead to a cash flow crisis. The company may need to raise additional capital.

Investor Verification Checklist

• Operating Viability: Verify the conversion rate of the six new BVA-100 trial agreements into paid sales, as the core business remains unprofitable without investment income.
• Investment Concentration: Assess the risk of the portfolio being heavily weighted in utility stocks and the impact of interest rate changes on valuation and borrowing costs.
• Internal Control Remediation: Monitor the effectiveness of the new accounting staff and the timeline for resolving the material weakness in internal controls.
• Cash Burn Rate: Track the monthly cash burn from operations against the current cash balance ($37,818) and the availability of margin loans ($5.8M) to ensure solvency.
• Restatement Impact: Confirm that the restatements for 2003-2005 have been fully resolved and that no further adjustments are anticipated.